tiotropium (Spiriva)

05/01/2009 - "A large body of evidence is available at present on the safety and efficacy of tiotropium in COPD, with dry mouth being the most common adverse event. "
12/01/2008 - "Tiotropium appears to be the best option as a first-line drug for patients with moderate-to-severe COPD because of its ability to sustain bronchodilator effect, improve quality of life, reduce COPD exacerbations, and reduce health resource usage. "
01/01/2014 - "To evaluate data from randomised controlled trials (RCTs) comparing the efficacy of tiotropium and placebo in patients with COPD, upon clinically important endpoints. "
01/01/2012 - "To evaluate data from randomised controlled trials (RCTs) comparing the efficacy of tiotropium and placebo in patients with COPD, upon clinically important endpoints. "
03/01/2010 - "Results of recent clinical trials support findings from earlier trials in patients with moderate to very severe COPD demonstrating significant benefits of tiotropium compared to placebo, including sustained increases in lung function, reductions in exacerbations and risk of exacerbation-related hospitalizations, and improvement in health status. "

11/27/2015 - "The results of studies on severe asthma showed that adding tiotropium to a treatment with high doses of an ICS plus LABA results in further improvement in lung function, increases the time to the first severe exacerbation of asthma and to worsening of asthma, and improves asthma control. "
12/01/2014 - "The addition of tiotropium may be beneficial for patients with poorly controlled asthma, although exacerbation or safety issues should be clarified in long-term trials before its wide use in asthma."
05/01/2013 - "Two large randomized controlled trials support the safety and efficacy of adding tiotropium to the treatment regimen of select patients with poorly controlled asthma already receiving combination high-dose glucocorticosteroid/long-acting β-agonist (LABA) therapy. "
01/01/2015 - "The analyses performed demonstrated a high efficacy of tiotropium in terms of improved lung function parameters and prolonged time to the first asthma exacerbation. "
12/01/2014 - "Tiotropium also reduced the risk of severe acute exacerbation (OR 0.73, 95%CI 0.56-0.96) and improved Asthma Quality-of-Life Questionnaire score significantly by 0.10 (95%CI 0.04-0.16). "

10/01/2010 - "Aclidinium and tiotropium also significantly increased FEV(1) (p < 0.01) and improved the perception of dyspnea compared with placebo at all measured time points from 10 minutes to 3 hours post-dose. "
03/01/2010 - "The use of tiotropium in isolation resulted in significant improvement in dyspnea at baseline (mean Medical Research Council scale score reduced from 3.0 to 2.5) and at the end of 6MWT (mean Borg scale score reduced from 6.1 to 4.5), and the differences were significant (p < 0.05 for both). "
12/01/2008 - "Tiotropium also provides superior bronchodilation and improvement in dyspnea at all time points, although onset of bronchodilation is slower than with long-acting beta(2)-agonists. "
12/01/2004 - "Clinically relevant outcomes such as the relief of dyspnea, improvement in the quality of life (health status), and reductions in the frequency and severity of acute exacerbations have been consistently obtained with tiotropium in clinical trials. "
01/01/2006 - "Tiotropium in combination with pulmonary rehabilitation produces clinically improvement in dyspnea, health status endurance of constant work compared to pulmonary rehabilitation alone. "

07/01/2015 - "Tiotropium bromide is an anticholinergic bronchodilator used in the management of chronic obstructive pulmonary disease. "
01/22/2012 - "Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease."
12/01/2006 - "Evaluating the pharmacoeconomic effect of adding tiotropium bromide to the management of chronic obstructive pulmonary disease patients in Singapore."
12/01/2005 - "Does pulmonary rehabilitation give additional benefit over tiotropium therapy in primary care management of chronic obstructive pulmonary disease? "
02/01/2002 - "Tiotropium in the management of chronic obstructive pulmonary disease."

05/30/2007 - "Tiotropium bromide may have a beneficial influence on airway remodeling processes in chronic airway diseases through antiproliferative effects on fibroblasts and myofibroblasts."
07/01/2012 - "This study suggests that tiotropium bromide might have an inhibitory effect on airway remodeling in a murine model of chronic asthma. "
07/01/2012 - "Effect of tiotropium bromide on airway remodeling in a chronic asthma model."
10/01/2007 - "The aim of the present study was to investigate other aspects of airway remodelling and to compare the effectiveness of tiotropium to the glucocorticosteroid budesonide. "
10/01/2007 - "Inhibition of allergen-induced airway remodelling by tiotropium and budesonide: a comparison."